Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 34028551.
- Also identified by DOI 10.1001/jamanetworkopen.2021.10950 and PMC identifier 8144926.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This comparative effectiveness research compares survival end points and response rates among patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib and cabazitaxel using results from 2 phase 3 randomized clinical trials.
Medical subject headings
- Antineoplastic Agents
- Neoplasm Metastasis
- Phthalazines
- Piperazines
- Prostatic Neoplasms, Castration-Resistant
- Taxoids